Which treatment option is employed for resistant cases of minimal change disease?

In cases of minimal change disease that are resistant to standard treatment with corticosteroids, high-dose corticosteroids may be utilized as a subsequent treatment strategy. Minimal change disease is primarily characterized by nephrotic syndrome and often responds well to corticosteroids; however, some patients may not achieve remission with the standard initial doses. When standard doses are ineffective, escalating the dose of corticosteroids can sometimes lead to a favorable response, effectively managing symptoms and addressing proteinuria.

The use of high-dose corticosteroids is based on their ability to modulate the immune response and reduce inflammation related to the disease. While other treatment options exist for different renal conditions, the management of resistant minimal change disease specifically involves intensified corticosteroid therapy as a first-line adjustment.

Other options, such as immunosuppressants, could be considered in certain scenarios where corticosteroids are ineffective or if the patient has frequent relapses. However, high-dose corticosteroids remain the primary treatment for addressing resistance early in the management process of minimal change disease.